Literature DB >> 16493495

Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs.

Mariska L M Lieuw-a-Fa1, Casper G Schalkwijk, Marten Engelse, Victor W M van Hinsbergh.   

Abstract

In diabetes mellitus an increased risk exists for vascular complications. A role for advanced glycation endproducts (AGEs) in the acceleration of vascular disease has been suggested. Nepsilon-(carboxymethyl)lysine (CML)- and methylglyoxal (MGO)-modified proteins have been identified as major AGEs. The interaction of these AGEs with the human endothelial cells and macrophages was studied. Changes in adhesion molecule expression, i.e. vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin were determined by cell-bound Elisa on human endothelial cells after incubation with CML-modified albumin and MGO-modified albumin. The presence of the full-length receptor of AGEs (RAGE) and splice variants of RAGE was determined by specific RT-PCR. In addition, binding studies were performed with CML- and MGO-modified albumin to endothelial cells and P388D1 macrophages. We demonstrated that CML-albumin or MGO-albumin did not induce activation of endothelial cells as measured by the expression of adhesion molecules, while, under the same conditions, TNF-alpha did. No specific binding of CML-albumin and MGO-albumin on these cells was found. In contrast to endothelial cells, a specific binding of MGO-albumin to P388D1 macrophages was demonstrated, which could be competed by ligands of scavenger receptors. In human umbilical vein and microvascular endothelial cells we found the N-truncated and C-truncated splice variants of RAGE. In conclusion, under our experimental conditions no CML- or MGO-albumin-induced increase in adhesion molecule expression was found on endothelial cells. In agreement with this, no binding of these AGEs was found to endothelial cells. The existence of splice variants of RAGE in endothelial cells might explain the lack of interaction of extracellular AGEs with these cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493495     DOI: 10.1160/TH05-04-0248

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Exploring post-translational arginine modification using chemically synthesized methylglyoxal hydroimidazolones.

Authors:  Tina Wang; Rendy Kartika; David A Spiegel
Journal:  J Am Chem Soc       Date:  2012-05-16       Impact factor: 15.419

Review 2.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

3.  The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1.

Authors:  M G A van Eupen; M T Schram; H M Colhoun; N M J Hanssen; H W M Niessen; L Tarnow; H H Parving; P Rossing; C D A Stehouwer; C G Schalkwijk
Journal:  Diabetologia       Date:  2013-04-26       Impact factor: 10.122

4.  Human muscle satellite cells show age-related differential expression of S100B protein and RAGE.

Authors:  Sara Beccafico; Francesca Riuzzi; Cristina Puglielli; Rosa Mancinelli; Stefania Fulle; Guglielmo Sorci; Rosario Donato
Journal:  Age (Dordr)       Date:  2010-12-08

5.  Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress.

Authors:  O Brouwers; P M Niessen; G Haenen; T Miyata; M Brownlee; C D Stehouwer; J G De Mey; C G Schalkwijk
Journal:  Diabetologia       Date:  2010-02-26       Impact factor: 10.122

6.  Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.

Authors:  Jhih-Syuan Liu; Tsung-Ju Chuang; Jui-Hung Chen; Chien-Hsing Lee; Chang-Hsun Hsieh; Tsung-Kun Lin; Fone-Ching Hsiao; Yi-Jen Hung
Journal:  Endocrine       Date:  2015-02-11       Impact factor: 3.633

7.  Specific local cardiovascular changes of Nepsilon-(carboxymethyl)lysine, vascular endothelial growth factor, and Smad2 in the developing embryos coincide with maternal diabetes-induced congenital heart defects.

Authors:  Pauline A M Roest; Daniël G M Molin; Casper G Schalkwijk; Liesbeth van Iperen; Parri Wentzel; Ulf J Eriksson; Adriana C Gittenberger-de Groot
Journal:  Diabetes       Date:  2009-02-02       Impact factor: 9.461

8.  Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction in Cholesterol Efflux-Related Gene Expression in Macrophages.

Authors:  Ligia Shimabukuro Okuda; Rodrigo Tallada Iborra; Paula Ramos Pinto; Ubiratan Fabres Machado; Maria Lucia Corrêa-Giannella; Russell Pickford; Tom Woods; Margaret Anne Brimble; Kerry-Anne Rye; Marisa Passarelli
Journal:  Mediators Inflamm       Date:  2020-01-14       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.